Victoria Richon

Victoria Richon, Ph.D. has served on the board of directors since September 2019. Dr. Richon currently serves as the President and Chief Executive Officer of Ribon Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions. Prior to Ribon, she was vice president, global head of discovery and early development at Sanofi Oncology in Cambridge, Mass., where she was responsible for overseeing the discovery research and translational medicine of drug candidates emerging from Sanofi’s drug discovery oncology projects. Dr. Richon served as vice president of biological sciences at Epizyme from 2008 to 2012 and played a key role in bringing forward two first-in-class agents from initiation of discovery to clinical trials, including tazemetostat. Before her tenure at Epizyme, she was senior director and department head of cancer biology and therapeutics at Merck & Co., Inc., and before that, was a co-founder at Aton Pharma, Inc. Dr. Richon began her scientific career as a postdoctoral fellow in the Department of Cell Biology at Memorial Sloan-Kettering Cancer Center and is an author on more than 100 peer-reviewed publications. She received her B.A. in chemistry from the University of Vermont and her Ph.D. in biochemistry from the University of Nebraska Medical Center Eppley Institute for Research in Cancer and Allied Diseases.